

# Index

## A

ACEI/ARB, 108  
ACEIs. *See* Angiotensin-converting enzyme inhibitors (ACEIs)  
Adenylyl cyclase 6, 27  
Akt, 26  
Albuminuria, 90  
Allelic heterogeneity, 87  
AMP-activated protein kinase (AMPK), 50  
AMPK activator, 78  
Angiotensin converting enzyme (ACE), 88  
Angiotensin-converting enzyme inhibitors (ACEIs), 78, 107  
Angiotensin receptor blockers (ARBs), 107  
AntagomiR, 65  
Anterograde transport, 47  
AntimiR, 65  
Apelin, 95  
Apelin-APJ axis, 95  
Apoptosis, 29  
ARBs. *See* Angiotensin receptor blockers (ARBs)  
Arginine vasopressin (AVP), 96  
Asymmetric dimethylarginine (ADMA), 94  
AVP. *See* Arginine vasopressin (AVP)  
AVP receptor blockers, 106  
5-Aza-2'-deoxycytidine, 60, 63

## B

Basal bodies, 47  
Bax, 30  
Bcl-2, 30  
Biomarker, 86  
Bosutinib, 6  
B-Raf, 26

## C

Calcium, 49  
Calcium channels, 51  
Calcium-induced calcium release (CICR), 53  
cAMP. *See* Cyclic adenosine monophosphate (cAMP)  
cAMP response element binding protein (CREB), 27  
Cardiac defects, 4  
Caspases, 29  
 $\beta$ -Catenin dependent, 16  
 $\beta$ -Catenin independent, 16  
CDCA, 53  
CDKs. *See* Cyclin-dependent kinases (CDKs)  
CDK5, 31  
Cell cycle, 25  
Cell proliferation, 25  
Chromatin, 59  
Chronic kidney disease (CKD), 108  
CICR. *See* Calcium-induced calcium release (CICR)  
Cilia, 45  
Ciliogenesis, 46  
Ciliopathies, 51  
CKD. *See* Chronic kidney disease (CKD)  
c-Myc, 30  
Computed tomography (CT), 93  
Congenital polycystic kidney (cpk), 73  
Consortium for Radiologic Imaging Study of PKD (CRISP), 87  
Copeptin, 96  
CpG islands, 60  
Cpk. *See* Congenital polycystic kidney (cpk)  
CREB. *See* cAMP response element binding protein (CREB)  
Curcumin, 112

- Cyclic adenosine monophosphate (cAMP), 5, 15, 27
- Cyclin-dependent kinases (CDKs), 26
- Cys1 gene, 73
- Cyst rupture, 90
- Cytochrome c, 29
- Cytosine-guanosine dinucleotides (CpGs), 60
- D**
- de novo* methylation, 60
- de novo* mutation, 4
- Death receptors, 29
- Development, 50
- Dialysis, 4
- Dicer, 61
- Dickkopf 3 (DKK3), 88
- DNA methylation, 7, 60, 61
- DNA methyltransferases (DNMTs), 60
- Drosha, 61
- Dynein-2, 47
- E**
- 4E-binding protein 1, 28
- EGF. *See* Epidermal growth factor (EGF)
- eIF2, 28
- Endothelial nitric oxide synthase, 88
- Epidermal growth factor (EGF), 27
- Epigenetic modification, 88
- Epigenetic regulation, 59
- ESRD, 4
- Everolimus, 6, 76
- Exportin-5, 61
- Extracellular matrix, 7
- Extracellular signal-regulated kinase (ERK), 26
- F**
- Fibrosis, 36
- Filtration, 7
- Folate-conjugated drugs, 77
- Food restriction, 79
- G**
- G-protein coupled receptors (GPCRs), 30
- Gene-body methylation, 60
- Genome-wide DNA methylation, 62
- Germline mutation, 4
- Glioma (Gli), 48
- Glomerular filtration rate (GFR), 91
- Gross hematuria, 90
- Growth factors, 5
- H**
- Hairpin structure, 61
- HALT-PKD study, 107
- Han:SPRD Cy rat model, 74
- Han:SPRD rat, 29
- HDAC inhibitor, 64
- Hedgehog, 48
- Hematuria, 90
- Hepatocystic disease, 4
- High water intake, 106
- Histone, 59
- Histone deacetylases (HDACs), 60
- Histone methyltransferases (HMTs), 60
- Histone modification, 60
- HMG-CoA reductase, 77
- Homeostasis, 7
- Homeostatic, 5
- Hypermethylation, 60, 62
- Hypertension, 4, 90, 107
- Hypomorphic alleles, 88
- I**
- IAPs. *See* Inhibitor of apoptosis proteins (IAPs)
- Ift20-targeted mouse model, 73
- Inflammation, 35
- Inhibitor of apoptosis proteins (IAPs), 29
- Inositol triphosphate receptor (IP3R), 26
- Integrins, 7
- Intracranial aneurysms, 4
- Intraflagellar transport, 47
- J**
- JAK-STAT, 16, 38
- Janus kinase, 28
- Juvenile cystic kidney (jck), 52, 73
- K**
- KD019, 112
- Kif3a, 53
- Kinesin-II, 47
- L**
- Laminins, 7
- Left ventricular mass index (LVMI), 108

Linkage analysis, 87  
 Lkb1, 50  
 Locus heterogeneity, 87  
 Lovastatin, 79  
 Luminal flow, 49  
 LVMI. *See* Left ventricular mass index (LVMI)

**M**  
 Macrophage, 36  
 Magnetic resonance imaging (MRI), 93  
 Mammalian target of rapamycin (mTOR) inhibitors, 76–77  
 Manifestations, 4  
 MAPKs. *See* Mitogen-activated protein kinases (MAPKs)  
 Matrix metalloproteinases (MMPs), 7, 39  
 Mature miRNA, 61  
 MDRD, 107  
 Mechanosensors, 50  
 Mechanosignaling, 49  
 mechanotransduction, 50  
 MEK, 26  
 MEK inhibitors, 77  
 Methylated cytosine (5-methylcytosine), 60  
 Microalbuminuria, 91  
 MicroRNA, 8, 61  
 Mitogen-activated protein kinases (MAPKs), 26  
 MMPs. *See* Matrix metalloproteinases (MMPs)  
 Modification of Diet in Renal Disease (MDRD), 91  
 Modifier gene effect, 88  
 Monocyte chemoattractant protein-1 (MCP-1), 6, 36, 37, 92, 94, 114  
 Motile cilia, 46  
 mTOR, 16, 26, 50  
 mTOR signaling, 6  
 mTORC1, 50  
 mTORC2, 50

**N**  
 N-acetyl- $\beta$ -D glucosaminidase (NAG), 94  
*Nek8* gene, 52, 73  
 Neutrophil gelatinase-associated lipocalin (NGAL), 94  
 NF- $\kappa$ B, 37  
 Nuclear RNase III enzyme, 61

**O**

Oak ridge polycystic kidney (ORPK) mouse, 72  
 Octreotide, 75, 111

**P**

p21Waf1, 28  
 P53, 30  
 PC1, 13  
 PC2, 14  
 PERK, 28  
 Phosphatidylinositide 3-kinases, 28  
 PKD rodent models, 72  
 PKD1, 13  
 Pkd1-targeted mice, 72  
 PKD2, 13  
 Pkd2 constitutive knockout mice, 72  
 PKD2 transgenic mice, 72  
*PKHD1*, 4  
 Polymorphism, 88  
 Pravastatin, 77  
 Pre-miRNA, 61  
 Primary cilia, 45  
 Pri-miRNA, 61  
*PRKCSH*, 3  
 Proliferation, 50  
 Protein kinase B, 28  
 Proteinuria, 90  
 Ptch1, 48  
 Pyrrolidine dithiocarbamate, 78  
 Pyuria, 91

**R**

Raf inhibitor, 77  
 Rapamycin, 6, 76, 109  
 RAS blockers, 109  
 Renin-angiotensin system (RAS), 28, 90  
 Retrograde transport, 47  
 Rheb, 28  
 RNA polymerase II, 61  
 RNA-induced silencing complex (RISC), 61  
 Roscovitine, 79

**S**

S-adenosyl methionine, 60  
*SEC63*, 3  
 Second hit, 4, 17

Secreted Frizzled-related protein 4 (sFRP4), 97  
 Serum creatinine, 91  
 Shear stress, 50  
 Signal transducer and activator of transcription, 28  
 Signaling pathways, 15  
 Sirolimus, 6, 76, 109  
 Smo, 48  
 Somatostatin analogs, 30, 75–76  
 Sorafenib, 6  
 Spironolactone, 112  
 STAT3, 6  
 Statins, 77  
 Stem-loop structure, 61  
 Steviol, 78  
 SUISSE study, 109  
 Syndecans, 7

## T

TEMPO 3:4 trial, 75  
 Tesevatinib, 112  
 TGF- $\beta$ , 38  
 Third hit, 4  
 TIMP, 39  
 Tissue inhibitors of metalloproteinases (TIMPs), 7  
 TNF- $\alpha$ , 37  
 Tolvaptan, 75  
 Transplantation, 4

Trichostatin A, 64  
 Triptolide, 112  
 TRPC1, 27  
 TRPV4, 27  
 TSC1/2, 27  
 $\alpha$ -Tubulin, 64  
 Tumor suppressor genes, 60  
 $\alpha$ 1 Type IV collagen, 7

## U

Ultrasonography, 93  
 3'-Untranslated region, 61  
 Urinary angiotensinogen, 95  
 Urinary tract infection(UTI), 91

## V

Vasopressin, 27  
 Vasopressin V2 receptor (V2R), 6, 27  
 Vasopressin V2 receptor antagonist (V2RAs), 30, 75, 110

## W

Wnt, 39, 52  
 Wnt signaling pathways, 16

## Z

Zebularine, 63